STAT3 and primary cutaneous T-cell non-Hodgkin lymphoma: The small‐molecule STAT3/5 degraders, IQDMA, a multi‐kinase inhibitor, and PAK kinase inhibitor exhibited remarkable potency in abolishing L‐CTCL cell growth in vitro and ex vivo, whereby PAK kinase inhibition was specifically selective for primary L‐CTCL cells with STAT3/5 gains.